Korea FilingsFull brief — $39

GC Biopharma Corp.

(주)녹십자 · KOSPI: 006280 · Pharmaceuticals and medicinal chemicals

Key facts

Korean name
(주)녹십자
Market / ticker
KOSPI · 006280
Industry
Pharmaceuticals and medicinal chemicals
Established
1969-11-01
Fiscal year ends
December
Website
www.gcbiopharma.com
DART corp code
00129679
Latest revenue
₩1.99T (FY2025)

Items worth checking

No rule-based items found in the latest annual report or the last 12 months of filings. This is a limited automated check, not a clean bill of health.

Financial summary

KRWFY2023FY2024FY2025
Revenue₩1.63T₩1.68T₩1.99T
Operating income₩34.4B₩32.1B₩69.1B
Net income−₩19.8B−₩42.6B−₩29.7B
Total assets₩2.64T₩2.74T₩2.97T
Total liabilities₩1.10T₩1.26T₩1.58T
Total equity₩1.54T₩1.48T₩1.39T
Share capital₩58.4B₩58.4B₩58.4B

Consolidated statements · FY2025 operating margin 3.5% · liabilities to equity 113% · Annual report FY2025 (Korean original)

Auditor opinions

PeriodAuditorOpinion
Term 57 (current)한영회계법인Unqualified
Term 56 (prior)한영회계법인Unqualified
Term 55 (two years prior)한영회계법인Unqualified

Largest shareholder history

No change history reported in the latest annual report.

Recent filings

DateFilingOriginal
2026-08-14Half-year report (2026.06)DART
2026-08-07Officer / major shareholder ownership reportDART
2026-07-31Fair trade compliance program status (notice)DART
2026-07-31Preliminary consolidated operating results (fair disclosure)DART
2026-07-16New facility investmentDART
2026-07-10Amended: Material event reportDART
2026-07-09Amended: Material event reportDART
2026-07-01Change in shareholdings of largest shareholderDART
2026-07-01Large shareholding (5%+) reportDART
2026-06-22Change in shareholdings of largest shareholderDART
2026-06-22Officer / major shareholder ownership reportDART
2026-06-01Corporate governance reportDART
2026-05-27Material event reportDART
2026-05-15Quarterly report (2026.03)DART
2026-05-11Change in shareholdings of largest shareholderDART
2026-05-08Preliminary consolidated operating results (fair disclosure)DART
2026-05-06Material management matterDART
2026-03-31Decision to dispose of shares of another companyDART
2026-03-31Amended: Annual general meeting resultsDART
2026-03-27Change in shareholdings of largest shareholderDART

Showing the 20 most recent of 49 filings. The full brief lists all of them.

Full brief on GC Biopharma Corp. — $39 Get the full brief

For business customers. EU companies: enter your VAT number at checkout and no VAT is charged (reverse charge).

Other Korean companies in Pharmaceuticals and medicinal chemicals

Data generated 2026-09-16 from OpenDART.

This page summarizes public filings from DART, the official electronic disclosure system of Korea. It is not investment, credit or legal advice. Figures are shown in the currency the company reports in. Titles and labels are machine-translated and may contain errors — always check the linked original filing. Source: OpenDART, Financial Supervisory Service, Korea.